These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 36344074)
41. Discovery of CFTR modulators for the treatment of cystic fibrosis. Lopes-Pacheco M; Pedemonte N; Veit G Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716 [TBL] [Abstract][Full Text] [Related]
46. Small-molecule drugs for cystic fibrosis: Where are we now? Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977 [TBL] [Abstract][Full Text] [Related]
47. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768 [TBL] [Abstract][Full Text] [Related]
49. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059 [TBL] [Abstract][Full Text] [Related]
50. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA; Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085 [TBL] [Abstract][Full Text] [Related]
52. Impact of highly effective CFTR modulator therapy on digital clubbing in patients with cystic fibrosis. Mahlen T; Barton L; Roberts D J Cyst Fibros; 2022 Sep; 21(5):861-865. PubMed ID: 35915048 [TBL] [Abstract][Full Text] [Related]
53. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Gramegna A; Contarini M; Aliberti S; Casciaro R; Blasi F; Castellani C Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824306 [TBL] [Abstract][Full Text] [Related]
54. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449 [TBL] [Abstract][Full Text] [Related]
55. A new era for people with cystic fibrosis. Bierlaagh MC; Muilwijk D; Beekman JM; van der Ent CK Eur J Pediatr; 2021 Sep; 180(9):2731-2739. PubMed ID: 34213646 [TBL] [Abstract][Full Text] [Related]
56. Current state of CFTR modulators for treatment of Cystic Fibrosis. Despotes KA; Donaldson SH Curr Opin Pharmacol; 2022 Aug; 65():102239. PubMed ID: 35609385 [TBL] [Abstract][Full Text] [Related]
57. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Barry PJ; Taylor-Cousar JL Curr Opin Pulm Med; 2021 Nov; 27(6):554-566. PubMed ID: 34420018 [TBL] [Abstract][Full Text] [Related]
58. Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators. Sathe M; Moshiree B; Aliaj E; Lee M; Hudson J; Gifford A; Attel S; Gamel B; Freedman SD; Schwarzenberg SJ; Freeman AJ Pediatr Pulmonol; 2023 Mar; 58(3):811-818. PubMed ID: 36448312 [TBL] [Abstract][Full Text] [Related]
60. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum. Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]